Table 3 Efficacy of prime–boost COVID-19 vaccination in patients with kidney failure
From: Vaccination in patients with kidney failure: lessons from COVID-19
KRT | Post-vaccination time (weeks) | Sample (n) | Efficacy parameter | BNT162b2 | mRNA-1273 | Ad26.COV2.S | ChAdOx-1 nCoV-19 | Ref. |
|---|---|---|---|---|---|---|---|---|
HD | 2 | 519 | Frequency of detectable humoral response | 90.4% | 97.2% | 16.7% | NA | |
HD | 2–3 | 143 | Frequency of detectable neutralizing response | 34.1% | 77.3% | NA | NA | |
HD | 4 | 94 | Frequency of detectable humoral response | 81.8% | NA | 70.6% | NA | |
Txa | 4 | 649 | Frequency of detectable humoral response | 48.8% | 59.6% | NA | NA | |
HD | 3 | 205 | Frequency of detectable humoral response | 92.0% | 98.0% | NA | NA | |
HD | >7 | 5,318 | Positive PCR incidence rate (per 1,000 patient-weeks) | 1.4 | NA | 1.5 | NA | |
Tx | 2–3 | 142 | Frequency of detectable humoral response | 47.6% | 62.2% | NA | NA | |
Magnitude titre (AU/ml) | <111 | 255 | NA | NA | ||||
HD | 2–4 | 1,583 | Frequency of detectable humoral response | 95.7% | 97.4% | 41.6% | NA | |
HD | 2 | 1,528 | Frequency of detectable humoral response | 87.0% | 96.1% | 25.5% | NA | |
PD | NA | |||||||
Tx | 2–6 | 25 | Frequency of detectable humoral response | 25.0% | 25.0% | NA | NA | |
HD | 3 | 116 | Frequency of detectable humoral response | 94.9% | 98.7% | NA | NA | |
Magnitude titre (BAU/ml) | 676 | 1507 | NA | NA | ||||
HD | 2–4 | 148 | Frequency of detectable humoral response | 85.8% | 93.3% | NA | NA | |
HD | 12–22 | 10,576 | Positive PCR incidence rate (per 10,000 patient-days) | 1.47 | 0.91 | 2.42 | NA | |
PD | NA | |||||||
HD | 2–4 | 64 | Frequency of detectable humoral response | 93.0%b | 33.0% | NA | ||
Tx | 4 | 768 | Frequency of detectable humoral response | 65.6% | NA | NA | 43.6% | |
Frequency of detectable cellular response | 17.5% | NA | NA | 5.1% | ||||
Magnitude titre (BAU/ml) | 58 | NA | NA | 7.1 | ||||
HD | 4–5 | 1,136 | Frequency of detectable humoral response | 87.5% | 97.0% | NA | NA | |
Tx | 333 | 49.0% | 26 | NA | NA | |||
HD | 4–5 | 543 | Frequency of detectable humoral response | 76.5% | 87.8% | NA | NA | |
Magnitude titre (AU/ml) | 258 | 1,230 | NA | NA | ||||
Magnitude cellular response | 0.497 | 0.809 | NA | NA | ||||
HD | 3–4 | 138 | Frequency of detectable humoral response | 76.9% | 100.0% | NA | NA | |
PD | NA | NA | ||||||
HD | Magnitude titre (AU/ml) | 16.6 | 16.2 | NA | NA | |||
PD | NA | NA | ||||||
Tx | 133 | Frequency of detectable humoral response | 56.0% | 76.2% | NA | NA | ||
Magnitude titre (AU/ml) | 12.4 | 5.6 | NA | NA | ||||
